ST. LOUIS--(BUSINESS WIRE)--Thompson Street Capital Partners (TSCP), a private equity firm based in St. Louis, has partnered with management to acquire Seattle-based LifeSpan Biosciences, Inc., (LSBio). The Company is a founder-led developer and distributer of antibodies and related reagents primarily to the academic and pharmaceutical research markets via its e-commerce platform. Terms of the transaction were not disclosed.
LSBio (www.lsbio.com), originally founded as an immunohistochemistry (IHC) services provider in 1995, has evolved to offer a broad range of antibodies, kits, proteins and other biological reagents. The Company’s offerings include proprietary, value-added and third-party products. Researchers have long relied upon LSBio’s expertise to fulfill their molecular pathology needs. As part of its growth strategy, the Company plans to continue expanding its catalog of high-quality reagents, both through internal research and development and a targeted acquisition strategy.
Bob Dunn, a Managing Director and Head of Acquisitions at TSCP, said, “We’re excited to be partnering with the founders of LSBio. The Company fills a highly specific niche in its industry and enjoys a well-deserved reputation for excellence, innovation and customer service. LSBio’s ongoing mission is to expand upon its capabilities to provide the vital materials necessary for fueling important scientific research. We’re proud to help facilitate the ongoing growth of LifeSpan Biosciences.”
BroadOak Capital Partners served as LifeSpan Biosciences’ exclusive financial adviser. Achelous Partners acted as Thompson Street’s financial adviser.
About Thompson Street Capital Partners
Thompson Street Capital Partners (www.tscp.com) is a St. Louis-based private equity firm focused on investing in founder-led middle market businesses in the healthcare and life science services, software and technology services, and business services and engineered products sectors. Founded in 2000, the firm has acquired more than 100 companies and has managed more than $2.6 billion in equity. TSCP partners with management teams to increase value by accelerating growth, both organically and via acquisitions.